SCHEMBL3450563

SCHEMBL3450563

COc1ccc(Nc2nc(-c3ccccc3)cc(N3CCSCC3)n2)cc1F

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GALR1 P47211 8/20 0.58
GALR2 O43603 8/20 0.58
ABCG2 Q9UNQ0 2/20 0.46
ABCB1 P08183 1/20 0.46
ABCC1 P33527 1/20 0.46
HRH1 P35367 3/20 0.44
HRH4 Q9H3N8 3/20 0.44
IMPDH2 P12268 1/20 0.42
HRH2 P25021 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
PTGES O14684 1/20 0.40
LMNA P02545 1/20 0.39
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450918 0.88 TUBB4A (0.48) GALR1GALR2HRH1HRH4IMPDH2
SCHEMBL3453011 0.88 GALR1 (0.60) GALR1GALR2ABCG2ABCB1ABCC1
SCHEMBL3451772 0.87 GALR1 (0.56) GALR1GALR2ABCG2ABCB1ABCC1
SCHEMBL3450914 0.87 GALR1 (0.56) GALR1GALR2ABCG2ABCB1ABCC1
SCHEMBL10143491 0.80 GALR2 (0.82) GALR1GALR2AURKA
SCHEMBL5209575 0.78 GALR1 (0.47) GALR1GALR2ABCG2ABCB1ABCC1
SCHEMBL3451556 0.77 HRH4 (0.56) GALR1GALR2HRH1HRH4IMPDH2
SCHEMBL3452080 0.77 HRH4 (0.42) GALR2HRH1HRH4HRH2HRH3
SCHEMBL3452686 0.77 PTGS2 (0.53) HRH1HRH4HRH2HRH3GSK3B
SCHEMBL3449850 0.77 BCL6 (0.52) GALR1GALR2HRH1HRH4IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US claimed
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP claimed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS GALR1 3000/4885GALR2 2962/4885ABCG2 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.